Cytokine Signalling Forum


October 19

Facteurs de Risque d'Événements Cardiovasculaires Indésirables Majeurs Dans les Études de Phase III et de Prolongation à Long Terme du Tofacitinib chez les Patients Atteints de Polyarthrite Rhumatoïde

Christina Charles-Schoeman, Ryan DeMasi, Hernan Valdez, Koshika Soma, Lie-Ju Hwang, Mary G Boy, Pinaki Biswas, Iain B McInnes.
Ann Rheum Dis. 2019

Post hoc analyses of the six ORAL studies and two LTE’s suggested that after 24 weeks of TOF treatment, increases in HDL-c and decreases in the TC/HDL-c ratio appeared to be associated with reduced future MACE risk in RA patients. 52 MACE occurred in 4076 patients over 12873 patient-years of exposure. Separate Cox regression models were used to evaluate traditional CV risk factors’ association with time to first MACE at baseline and changes in lipid levels with time to future MACE ...

Mots clefs: JAK, Tofacitinib, Real World, Cardiovascular

Traduit par: Melissa Noack